Le Lézard
Classified in: Health
Subject: MAT

Park City Facial and Reconstructive Plastic Surgeon Dr. Eric Cerrati Reaches Milestone: One Hundred Five-Star Reviews on Google


Dr. Eric Cerrati, a top cosmetic, plastic & reconstructive surgery specialist in Salt Lake City, UT, has worked hard providing exceptional care and outstanding results to achieve this impressive number of five-star ratings through the Google platform.

PARK CITY, Utah, October 06, 2022 /PRNewswire-PRWeb/ -- A milestone worth celebrating was reached by Dr. Eric Cerrati and his Park City practice with the earning of 100 Google five-star reviews from his satisfied patients. Eric Cerrati, M.D. is double board certified and a leading expert in aesthetic and reconstructive facial plastic surgery. Recognizing that choosing facial cosmetic surgery can be a life-changing decision, Dr. Eric Cerrati treats all of his patients with the utmost respect and kindness. This approach, coupled with his five-star Google rating, attracts countless patients from across the country. Using his elite training and skill, he provides the most cutting-edge, advanced treatments available. Dr. Cerrati believes that the finest aesthetic outcomes are achieved through close doctor/patient collaboration, which is why he performs extensive consultations with all of his patients. He truly takes the time to carefully evaluate and develop a highly customized plan, focusing on all aspects of facial plastic surgery, including both surgical and non-surgical options, to help patients in the greater Salt Lake City area look his or her best. Facelifts, rhinoplasty, endoscopic browlift, blepharoplasty, facial fillers, Mohs reconstruction, scar revision and pediatric facial plastic surgery for vascular/congenital anomalies and more are offered by this talented plastic surgeon. Dr. Cerrati also provides patients with the most experience in craniofacial surgical procedures than other specialists in his area.

"This great accomplishment is the result of an outstanding team effort to consistently put our patients first," says Dr. Eric Cerrati.

More about Dr. Eric Cerrati:
Dr. Eric Cerrati received his medical degree from the Medical University of South Carolina in Charleston, SC. His post-doctoral training included a 5-year residency in otolaryngology-head and neck surgery at NYU. Dr. Cerrati spent a significant amount of time working with Dr. Milton Waner, the founder of the Vascular Birthmark Institute of New York. This provided him with unique training in pediatric facial plastic surgery, addressing the rarest congenital anomalies. Following his residency, he completed a prestigious fellowship at the Facial Plastic Surgery Center in Chicago. Dr. Cerrati also served as the Director of Facial Plastic & Reconstructive Surgery at the University of Utah. As a leader in his field, Dr. Cerrati speaks at numerous conferences and is a contributor to many medical journals and textbooks. In addition to treating his patients, Dr. Cerrati is also the official facial plastic surgeon to the Utah Jazz, U.S. Ski and Snowboard Association, U.S. Speedskating, U.S. Bobsled and Skeleton Federation and the International Olympic and Paralympic Medical Committees. Dr. Eric Cerrati's office is located at 1441 W. Ute Blvd, Ste 160 in Park City, UT. For more information, please visit http://www.drericcerrati.com or call (801) 497-6944.

Media Contact

Dr. Eric Cerrati, ERIC W. CERRATI, MD, FACS, 801-497-6944, [email protected]

 

SOURCE ERIC W. CERRATI, MD, FACS


These press releases may also interest you

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...



News published on and distributed by: